A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse

by Alvarez, E., Bowen, J.D, Caggiano, A.O, Eisen, A., Greenberg, B.M, Rodriguez, M., Warrington, A.E, Zhao, P.
Published 2022